Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 10, 2013

View Archived Issues

Small-molecule lipid II inhibitors identified as potential antibacterials

NDC-1308, a novel compound inducing remyelination and slowing clinical signs in EAE mice

S. pneumoniae whole-cell vaccine undergoes phase I study

Alkermes completes enrollment in pivotal study of aripiprazole lauroxil

Three clinical studies of Parkinson's disease candidate opicapone reported

WISP1 gene expression linked to adipose tissue differentiation and obesity

Gicare Pharma develops compounds for visceral pain

Novel PCSK9 expression inhibitors described in Kowa patent

U.S. researchers design prodrugs of riluzole

Mileutis divulges peptides for lactation disorders

Sysmex Inostics and Bayer HealthCare to develop blood-based companion diagnostic tests

Molecular Templates raises funds to advance MT-3724

The Medicines Company and Alnylam to advance ALN-PCSsc

Ariad Pharmaceuticals gives update on Iclusig development

Immunogenicity and efficacy of HIVAX vaccine: results of a first-in-human study

CGEN-15001 is effective in an animal model of type 1 diabetes

FDA accepts filing for Bunavail NDA

Promedior begins phase II study of PRM-151 in myelofibrosis

Phase I/II study of Portola Pharmaceuticals' dual SYK/JAK inhibitor commences

QRxPharma meets with the FDA regarding MoxDuo NDA

Novogen acquires new technology targeting the Tm5NM1 protein

Phase III bivalirudin trial enrolls first patient

Kowa seeks approval in Japan for K-115

Morphotek reports initiation of phase I study of MORAb-004 in pediatric patients

Positive risk-benefit leads Gilead to end phase III study of idelalisib early

Nycomed to return worldwide rights to veltuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...